Securian Asset Management Inc. Reduces Position in Zoetis Inc. $ZTS

Securian Asset Management Inc. cut its stake in shares of Zoetis Inc. (NYSE:ZTS) by 44.0% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 11,983 shares of the company’s stock after selling 9,419 shares during the quarter. Securian Asset Management Inc.’s holdings in Zoetis were worth $1,508,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in the stock. Vanguard Group Inc. boosted its holdings in Zoetis by 12.9% in the fourth quarter. Vanguard Group Inc. now owns 47,780,974 shares of the company’s stock valued at $6,011,802,000 after purchasing an additional 5,474,210 shares during the last quarter. Nordea Investment Management AB boosted its holdings in Zoetis by 79.2% in the fourth quarter. Nordea Investment Management AB now owns 4,932,787 shares of the company’s stock valued at $622,222,000 after purchasing an additional 2,179,578 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. boosted its holdings in Zoetis by 14.6% in the third quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 4,312,779 shares of the company’s stock valued at $631,046,000 after purchasing an additional 550,859 shares during the last quarter. Alliancebernstein L.P. boosted its holdings in Zoetis by 13.3% in the third quarter. Alliancebernstein L.P. now owns 4,241,357 shares of the company’s stock valued at $620,595,000 after purchasing an additional 496,320 shares during the last quarter. Finally, Fundsmith LLP boosted its holdings in Zoetis by 25.3% in the third quarter. Fundsmith LLP now owns 3,615,131 shares of the company’s stock valued at $528,966,000 after purchasing an additional 730,300 shares during the last quarter. 92.80% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research firms have commented on ZTS. William Blair reaffirmed an “outperform” rating on shares of Zoetis in a report on Monday, March 2nd. JPMorgan Chase & Co. lowered their price target on shares of Zoetis from $190.00 to $130.00 and set an “overweight” rating on the stock in a report on Friday. UBS Group lowered their price target on shares of Zoetis from $130.00 to $99.00 and set a “neutral” rating on the stock in a report on Friday. Stifel Nicolaus set a $105.00 price target on shares of Zoetis in a report on Friday. Finally, Piper Sandler reaffirmed a “neutral” rating and issued a $135.00 price target (down from $190.00) on shares of Zoetis in a report on Thursday, January 22nd. Seven research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $141.25.

Zoetis Stock Down 7.5%

ZTS opened at $76.62 on Tuesday. Zoetis Inc. has a twelve month low of $76.38 and a twelve month high of $172.23. The company has a quick ratio of 1.91, a current ratio of 3.15 and a debt-to-equity ratio of 2.80. The company has a 50-day moving average price of $116.50 and a 200 day moving average price of $122.77. The company has a market cap of $32.12 billion, a PE ratio of 12.71, a price-to-earnings-growth ratio of 1.29 and a beta of 0.87.

Zoetis (NYSE:ZTS) last released its quarterly earnings results on Thursday, May 7th. The company reported $1.53 earnings per share for the quarter, missing the consensus estimate of $1.60 by ($0.07). Zoetis had a return on equity of 66.85% and a net margin of 27.80%.The company had revenue of $2.26 billion for the quarter, compared to analyst estimates of $2.30 billion. During the same quarter last year, the company earned $1.48 EPS. The firm’s revenue for the quarter was up 2.9% on a year-over-year basis. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. Sell-side analysts expect that Zoetis Inc. will post 6.96 earnings per share for the current fiscal year.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.